In phase II, the median age was 56 (32-77), 24 patients (92%) were postmenopausal, 19 patients (73%) had hormone receptor-positive (HR+)/HER2+ breast cancer, and 14 (54%) had an ECOG PS of 0. This evidence concerns the gene ERBB2 and breast carcinoma.